In this study the efficacy and safety of GL was evaluated in a 52-weeks treatment of European chronic hepatitis C patients not responding or having contraindications to standard therapy (IFN + RBV or peg-IFNα + RBV). The gene discussed is IFNA1; the disease is chronic hepatitis C virus infection.